Skip to main content
. Author manuscript; available in PMC: 2021 Nov 28.
Published in final edited form as: Leukemia. 2021 May 28;35(10):2906–2916. doi: 10.1038/s41375-021-01284-4

Table 2.

Assessment of significance and inter-cohort heterogeneity in excess relative risk (ERR) per Gy (and 95% CI) in relation to dose to active bone marrow (ABM), total circulating lymphocytes and lymphatic tissues, for the six cohorts for which doses to the lymphoid system are available.†

Tissue dose used Number of case/deaths ERR/Gy (+95% CI) p-valuea Inter-cohort heterogeneity p-value
All lymphoma
Active bone marrow dose 474 −0.031 (−0.237, 0.251) 0.805 0.084
Lymphocyte dose 0.135 (−0.205, 0.621) 0.498 0.105
Lymphatic tissue dose 0.492 (−0.067, 1.332) 0.096 0.340b
Non-Hodgkin lymphoma + CLL
Active bone marrow dose 376 0.050 (−0.189, 0.387) 0.726 0.154b
Lymphocyte dose 0.294 (−0.114, 0.889) 0.190 0.377b
Lymphatic tissue dose 0.790 (0.083, 1.882) 0.022 0.862b
Non-Hodgkin lymphoma
Active bone marrow dose 342 0.019 (−0.224, 0.370) 0.896 0.333b
Lymphocyte dose 0.219 (−0.189, 0.828) 0.352 0.515b
Lymphatic tissue dose 0.631 (−0.045, 1.704) 0.074 0.854b
Chronic lymphocytic leukemia
Active bone marrow dose 34 0.331 (−0.989c, 2.283) 0.504 0.774b
Lymphocyte dose 1.113b (−1.888c, 5.329) 0.212b 0.914b
Lymphatic tissue dose 4.511 (−0.031, 20.020) 0.055 0.800b
Hodgkin lymphoma
Active bone marrow dose 71 −0.080 (−0.711c, 0.846) 0.825 0.900b
Lymphocyte dose −0.024 (−1.309c, 1.858) 0.975 0.896b
Lymphatic tissue dose 0.492 (−2.426c, 5.855) 0.749 0.911b
Multiple myeloma
Active bone marrow dose 96 −0.043 (−0.655c, 0.808) 0.890 0.964a
Lymphocyte dose 0.070 (−0.938c, 1.434) 0.877 0.970a
Lymphatic tissue dose 0.281 (−1.130c, 2.489) 0.640 0.983a
†

Obtained by fitting linear relative risk model, allowing for separate risk for diagnostically-exposed cohorts (Massachusetts TB, Canadian TB, US scoliosis), therapeutically-exposed cohorts (Israeli tinea capitis, Rochester thymus) and Japanese atomic bomb survivor Life Span Study (LSS), stratifying by cohort, sex, age and year of follow-up (using intervals of age and year of follow-up defined by person-year table, as in Appendix A Table A1). The six cohorts included in this analysis are those for which doses to the lymphoid system can be approximated from ABM doses (see Appendix B). Unless otherwise stated, all confidence intervals are based on the profile likelihood.

a

p-value of improvement in fit over null model (without dose trend).

b

indications of non-convergence

c

Wald-based CI